Global Prostate Cancer Therapeutic Market to 2020

Publisher Name :
Date: 11-May-2015
No. of pages: 76

Prostate Cancer remains a top priority for health systems around the world as incidence level rises, fueled by growing and aging populations. The main drivers for the prostate cancer market are the increase in the global aging population, innovation in drugs and developments in genomics and proteomics. The prostate cancer market faces some hindrances as well such as the high cost of prostate cancer drugs, low success rate of clinical trials and side effects of treatments among others.

Global Prostate Cancer - Key Therapies Analysis: The global market for prostate cancer therapeutics is increasing, driven primarily by the growth in the hormonal therapy markets. Chemotherapy was the second leading therapy for prostate cancer in 2014. However, growth in the targeted therapy is predicted to push chemotherapy back at the third position, while immunotherapy for prostate cancer stands at the last position in the prostate cancer therapeutics market.

Prostate Cancer Drugs Analysis: Zytiga leads the prostate cancer drugs market in 2014. Zytiga is facing stiff competition from Xtandi drugs which is expected to replace Zytiga as the leading prostate cancer drugs. In prostate cancer drugs market, Leuplin and Zoladex stands at the third and fourth position in 2014. The market share of both Leuplin and Zoladex is likely to plunge during the forecasting period. Lupron is standing at the fifth position. Bayer's targeted therapy drugs Xofigo is also rapidly catching up the market due to advantages such as increase in the overall survival and progression free survival with benign side effects profile.

Global Prostate Cancer Therapeutics Market to 2020 is a 76 page report with 43 Figures and 4 Tables. This report analyses the Prostate Cancer Therapy Market, Prostate Cancer Drugs Market, driving factors and challenges for prostate cancer market.  

The 4 Prostate Cancer Therapy Market covered in the report are as follows:


  • Hormonal Therapy

  • Chemotherapy

  • Immunotherapy

  • Targeted Therapy


The above 4 Therapy has been further analyzed in terms of drugs sales and forecast (2011 - 2020):

1. Global Prostate Cancer - Hormonal Therapy Drugs Market


  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists - Zytiga, Gonax

  • Luteinizing Hormone-Releasing Hormone (LHRH) Analogs - Lupron, Zoladex, Decapeptyl, Eligard, Vantas, Leuplin

  • Anti-Androgens - Casodex, Xtandi or MDV3100, Xtandi US or MDV3100


2. Global Prostate Cancer - Chemotherapy Drugs Market


  • Taxotere

  • Jevtana


3. Global Prostate Cancer - Immunotherapy Drugs Market


  • Provenge


4. Global Prostate Cancer - Targeted Therapy Drugs Market


  • Xofigo or Alpharadin


Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Global Prostate Cancer Therapeutic Market to 2020

Table of Contents

1. Executive Summary

2. Global Prostate Cancer Therapeutics Market

3. Global Prostate Cancer Incidence

4. Global Prostate Cancer Therapeutics Market Share & Forecast (2011 - 2020)
4.1 Global Prostate Cancer - Therapy Market Share
4.2 Global Prostate Cancer - Drugs Market Share

5. Global Prostate Cancer Therapy Market & Forecast (2011 - 2020)
5.1 Global Prostate Cancer Hormonal Therapy Market & Forecast
5.2 Global Prostate Cancer Chemotherapy Market & Forecast
5.3 Global Prostate Cancer Immunotherapy Market & Forecast
5.4 Global Prostate Cancer Targeted Therapy Market & Forecast

6. Global Prostate Cancer - Hormonal Therapy Drugs Sales & Forecast To 2020
6.1 Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
6.1.1 Zytiga
6.1.2 Gonax/ Firmagon
6.2 Luteinizing Hormone-Releasing Hormone (LHRH) Analogs
6.2.1 Lupron
6.2.2 Zoladex
6.2.3 Decapeptyl
6.2.4 Eligard
6.2.5 Vantas
6.2.6 Leuplin
6.3 Anti-Androgens
6.3.1 Casodex
6.3.2 Xtandi or MDV3100
6.3.3 Xtandi US or MDV3100

7. Global Prostate Cancer - Chemotherapy Drugs Market
7.1 Taxotere
7.2 Jevtana

8. Global Prostate Cancer - Immunotherapy Drugs Market
8.1 Provenge

9. Global Prostate Cancer - Targeted Therapy Drugs Market
9.1 Xofigo or Alpharadin

10. Global Prostate Cancer Market - Driving Factors
10.1 Innovative Drugs Driving the Market
10.2 Advancement in Oncology Therapeutic Area
10.3 Developments in Genomics & Proteomics

11. Global Prostate Cancer Market - Challenges
11.1 High Cost of Prostate Cancer Drugs
11.2 Adverse Events of Treatment
11.3 Low Success Rate in Clinical Testing For Oncology Drugs

List of Figures

Figure 2-1: Global - Prostate Cancer Therapeutics Market (Million US$), 2010 - 2014
Figure 2-2: Global - Forecast for Prostate Cancer Therapeutics Market (Million US$), 2015 - 2020
Figure 3-1: Global - Prostate Cancer Incidence (Number), 2007 - 2014
Figure 3-2: Global - Forecast for Prostate Cancer Incidence (Number), 2015 - 2020
Figure 5-1: Global Prostate Cancer - Hormonal Therapy Market (Million US$), 2011 - 2014
Figure 5-2: Global Prostate Cancer - Forecast for Hormonal Therapy Market (Million US$), 2015 - 2020
Figure 5-3: Global Prostate Cancer - Chemotherapy Market (Million US$), 2011 - 2014
Figure 5-4: Global Prostate Cancer - Forecast for Chemotherapy Market (Million US$), 2015 - 2020
Figure 5-5: Global Prostate Cancer - Immunotherapy Market (Million US$), 2011 - 2014
Figure 5-6: Global Prostate Cancer - Forecast for Immunotherapy Market (Million US$), 2015 - 2020
Figure 5-7: Global Prostate Cancer - Targeted Therapy Market (Million US$), 2013 - 2014
Figure 5-8: Global Prostate Cancer - Forecast for Targeted Therapy Market (Million US$), 2015 - 2020
Figure 6-1: Global - Zytiga Drugs Sales (Million US$), 2011 - 2014
Figure 6-2: Global - Forecast for Zytiga Drugs Sales (Million US$), 2015 - 2020
Figure 6-3: Global - Gonax/ Firmagon Drugs Sales (Million US$), 2012 - 2014
Figure 6-4: Global - Forecast for Gonax Drugs Sales (Million US$), 2015 - 2020
Figure 6-5: Global - Lupron Drugs Sales (Million US$), 2009 - 2014
Figure 6-6: Global - Forecast for Lupron Drugs Sales (Million US$), 2015 - 2020
Figure 6-7: Global - Zoladex Drugs Sales (Million US$), 2009 - 2014
Figure 6-8: Global - Forecast for Zoladex Drugs Sales (Million US$), 2015 - 2020
Figure 6-9: Global - Decapeptyl Drugs Sales (Million US$), 2009 - 2014
Figure 6-10: Global - Forecast for Decapeptyl Drugs Sales (Million US$), 2015 - 2020
Figure 6-11: Global - Eligard Drugs Sales (Million US$), 2009 - 2014
Figure 6-12: Global - Forecast for Eligard Drugs Sales (Million US$), 2015 - 2020
Figure 6-13: Global - Vantas Drugs Sales (Million US$), 2009 - 2014
Figure 6-14: Global - Forecast for Vantas Drugs Sales (Million US$), 2015 - 2020
Figure 6-15: Global - Leuplin Drugs Sales (Million US$), 2009 - 2014
Figure 6-16: Global - Forecast for Leuplin Drugs Sales (Million US$), 2015 - 2020
Figure 6-17: Global - Casodex Drugs Sales (Million US$), 2009 - 2014
Figure 6-18: Global - Forecast for Casodex Drugs Sales (Million US$), 2015 - 2020
Figure 6-19: Global - Xtandi or MDV3100 Drugs Sales (Million US$), 2012 - 2014
Figure 6-20: Global - Forecast for Xtandi or MDV3100 Drugs Sales (Million US$), 2015 - 2020
Figure 6-21: Global - Xtandi US or MDV3100 Drugs Sales (Million US$), 2012 - 2014
Figure 6-22: Global - Forecast for Xtandi US or MDV3100 Drugs Sales (Million US$), 2015 - 2020
Figure 7-1: Global - Taxotere Drugs Sales (Million US$), 2011 - 2014
Figure 7-2: Global - Forecast for Taxotere Drugs Sales (Million US$), 2015 - 2020
Figure 7-3: Global - Jevtana Drugs Sales (Million US$), 2010 - 2014
Figure 7-4: Global - Forecast for Jevtana Drugs Sales (Million US$), 2015 - 2020
Figure 8-1: Global - Provenge Drugs Sales (Million US$), 2011 - 2014
Figure 8-2: Global - Forecast for Provenge Drugs Sales (Million US$), 2015 - 2020
Figure 9-1: Global - Xofigo or Alpharadin Drugs Sales (Million US$), 2013 - 2014
Figure 9-2: Global - Forecast for Xofigo or Alpharadin Drugs Sales (Million US$), 2015 - 2020
Figure 11-1: Therapeutic Categories - Overall Success Rate from Phase 1 through Likelihood of Approval (Percent), 2004 - 2010

List of Tables

Table 4-1: Global - Prostate Cancer Therapy Market Share (Percent), 2011 - 2014
Table 4-2: Global - Forecast for Prostate Cancer Therapy Market Share (Percent), 2015 - 2020
Table 4-3: Global - Prostate Cancer Drugs Market Share (Percent), 2011 - 2014
Table 4-4: Global - Forecast for Prostate Cancer Drugs Market Share (Percent), 2015 - 2020

  • Global Circulating Tumor Cells Market Research Report 2017
    Published: 10-Nov-2017        Price: US 2900 Onwards        Pages: 115
    In this report, the global Circulating Tumor Cells market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Circulating Tumor Cells in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Ch......
  • Biliary Tumor - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Biliary Tumor - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Biliary Tumor. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Biliary Tumor which can turn out to b......
  • Chemotherapy Induced Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Chemotherapy Induced Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Chemotherapy Induced Anemia. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Chemother......
  • Larynx Cancer -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Larynx Cancer - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Larynx Cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Larynx Cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Larynx ......
  • Hodgkin's lymphoma (HL) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Hodgkin's lymphoma (HL) - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Hodgkin's lymphoma (HL) - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagno......
  • Lip and Oral Cavity Cancer -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Lip and Oral Cavity Cancer - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Lip and Oral Cavity Cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Lip and Oral Cavity Cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet m......
  • Liver cancer -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Liver cancer - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Liver cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Liver cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Liver cancer.......
  • Small Cell Lung Cancer - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Small Cell Lung Cancer - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Small Cell Lung Cancer for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Small Cell Lung Cancer . It enables unde......
  • Epithelial Ovarian Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Epithelial Ovarian Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Epithelial Ovarian Cancer. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Epithelial Ov......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs